Karen Keeshan

This paper identifies CD180 as a marker for chemoresistant stem-like blasts in KMT2A-rearranged paediatric AML, showing its absence on normal HSCs and its role as a therapeutic target.

This study identifies TRIB2 as a therapeutic target in AML by demonstrating that its degradation via PROTACs and small molecules can reverse chemoresistance and enhance chemotherapy efficacy.

This study identifies FAM30A as a regulator of LSC function in AML by interacting with MSI2 and RUNX1, enhancing stemness and chemoresistance.

This study shows that expressing caspase-resistant ROCK1 in B cell lymphoma mice prolongs survival by reducing cell numbers and creating a proliferation-suppressive bone marrow microenvironment.

The paper identifies EGFR/HER2 inhibitors that destabilize and degrade TRIB2 pseudokinase in cancer cells, suggesting potential for TRIB2-targeted therapies.